News
NBRVF
0.0002
0.00%
0.0000
Weekly Report: what happened at NBRVF last week (1007-1011)?
Weekly Report · 3d ago
Weekly Report: what happened at NBRVF last week (0930-1004)?
Weekly Report · 10/07 10:21
Weekly Report: what happened at NBRVF last week (0923-0927)?
Weekly Report · 09/30 10:17
Weekly Report: what happened at NBRVF last week (0916-0920)?
Weekly Report · 09/23 10:16
Weekly Report: what happened at NBRVF last week (0909-0913)?
Weekly Report · 09/16 10:11
Weekly Report: what happened at NBRVF last week (0902-0906)?
Weekly Report · 09/09 10:17
Weekly Report: what happened at NBRVF last week (0826-0830)?
Weekly Report · 09/02 10:19
Weekly Report: what happened at NBRVF last week (0819-0823)?
Weekly Report · 08/26 10:17
Weekly Report: what happened at NBRVF last week (0812-0816)?
Weekly Report · 08/19 10:10
Weekly Report: what happened at NBRVF last week (0805-0809)?
Weekly Report · 08/12 10:12
Weekly Report: what happened at NBRVF last week (0729-0802)?
Weekly Report · 08/05 10:18
Weekly Report: what happened at NBRVF last week (0722-0726)?
Weekly Report · 07/29 10:12
Weekly Report: what happened at NBRVF last week (0715-0719)?
Weekly Report · 07/22 10:13
Weekly Report: what happened at NBRVF last week (0708-0712)?
Weekly Report · 07/15 10:11
Weekly Report: what happened at NBRVF last week (0701-0705)?
Weekly Report · 07/08 10:12
Weekly Report: what happened at NBRVF last week (0624-0628)?
Weekly Report · 07/01 10:12
Weekly Report: what happened at NBRVF last week (0617-0621)?
Weekly Report · 06/24 10:16
Weekly Report: what happened at NBRVF last week (0610-0614)?
Weekly Report · 06/17 10:11
Weekly Report: what happened at NBRVF last week (0603-0607)?
Weekly Report · 06/10 10:12
Weekly Report: what happened at NBRVF last week (0527-0531)?
Weekly Report · 06/03 10:14
More
Webull provides a variety of real-time NBRVF stock news. You can receive the latest news about Nabriva Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About NBRVF
Nabriva Therapeutics PLC is a biopharmaceutical company. The Company is engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company's product is XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death.